Development of a Quantitative Systems Toxicology Model to Predict Drug-Induced Liver Injury in Pediatrics

Development of a Quantitative Systems Toxicology Model to Predict Drug-Induced Liver Injury in Pediatrics

Conference: ACoP
Software: DILIsym®, GastroPlus®

Drug-induced liver injury (DILI) is an underrecognized cause of pediatric liver disease which accounts for almost 20% of pediatric acute liver failure cases, and is a major reason for liver transplantation in the USA [1].

A Pediatric Pbpk Model of Atropine Gel To Predict Atropine Levels in Children With Neurological Disorders After Administration to Oral Cavity

A Pediatric Pbpk Model of Atropine Gel To Predict Atropine Levels in Children With Neurological Disorders After Administration to Oral Cavity

Conference: ACoP
Software: GastroPlus®

Sialorrhea, or excessive salivation, is a chronic and serious problem in children with cerebral palsy (CP) and neurodevelopmental disorders.[1–5] Sialorrhea occurs in up to 60% of children with CP...

Automated Concentration-QT data preparation, model selection and reporting in R

Automated Concentration-QT data preparation, model selection and reporting in R

Conference: International Society of Pharmacometrics
Software: Monolix®

Since the publication of the ICH E14 guidance in 2015, QT interval prolongation as-sessment can be carried out with a concentration-QTc modeling approach as part of single- or mul-tiple- dose escalation studies, instead of conducting a thorough QT/QTc study.

mlxDesignEval: A novel R package for design evaluation based on MonolixSuite, and its comparison to popED and PFIM

mlxDesignEval: A novel R package for design evaluation based on MonolixSuite, and its comparison to popED and PFIM

Conference: American Conference of Pharmacometrics
Software: Monolix®, Simulx®

Designing clinical trials to support population PK/PD modeling requires careful choices of sampling times, number of subjects, dose groups and other trial features to
ensure precise parameter estimation - with low relative standard errors [1].

Pharmacokinetic Studies and Synergistic Antitumor Effects of Cannabichromene and Cannabidiol in Drug-Resistant Breast Cancers

Pharmacokinetic Studies and Synergistic Antitumor Effects of Cannabichromene and Cannabidiol in Drug-Resistant Breast Cancers

Publication: Drug Delivery and Translational Research
Software: GastroPlus®

Triple-negative breast cancer (TNBC) is highly aggressive with limited treatment options, and resistance to doxorubicin (DOX) further compromises outcomes.